Harvard Bioscience, Inc. (HBIO) financial statements (2022 and earlier)

Company profile

Business Address 84 OCTOBER HILL RD
HOLLISTON, MA 01746
State of Incorp. DE
Fiscal Year End December 31
SIC 3826 - Laboratory Analytical Instruments (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments7,8218,3178,3358,1735,7335,596
Cash and cash equivalents7,8218,3178,3358,1735,7335,596
Receivables21,83417,76620,70421,46316,23615,746
Inventory, net of allowances, customer advances and progress billings27,58722,26222,06125,08721,35319,955
Inventory27,58722,26222,06125,08721,35319,955
Other current assets4,3413,3552,4723,1094,2134,175
Total current assets:61,58351,70053,57257,83247,53545,472
Noncurrent Assets
Operating lease, right-of-use asset6,8977,7618,463
Property, plant and equipment3,4153,9604,7765,8984,1404,296
Intangible assets, net (including goodwill)85,07491,74195,786103,06857,17356,712
Goodwill57,68958,59057,38157,30439,96938,032
Intangible assets, net (excluding goodwill)27,38533,15138,40545,76417,20418,680
Regulated entity, other noncurrent assets    (151)(104)
Other noncurrent assets5,3751,0922,2731,604324128
Other undisclosed noncurrent assets   2113331,261
Total noncurrent assets:100,761104,554111,298110,78161,81962,293
TOTAL ASSETS:162,344156,254164,870168,613109,354107,765
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4,9115,9725,94814,09910,34210,969
Accounts payable4,9115,9725,3397,3595,4046,196
Accrued liabilities   5,7624,5514,550
Taxes payable  609978387223
Deferred revenue4,2663,7713,949
Debt3,5152,0002,4244,3992,7652,372
Deferred revenue and credits633500
Other liabilities10,7627,4786,0911,588301760
Other undisclosed current liabilities1,8621,8326,9001,420  
Total current liabilities:25,31621,05325,31221,50614,04114,601
Noncurrent Liabilities
Long-term debt and lease obligation51,58353,76755,14158,7968,98311,374
Long-term debt, excluding current maturities45,09546,28646,91758,7968,98311,374
Operating lease, liability6,4887,4818,224
Liabilities, other than long-term debt2,0444,7532,7235,5875,4309,594
Accounts payable and accrued liabilities   3,2861,4663,177
Deferred tax liabilities, net2,3013,9646,417
Deferred income tax liabilities1,5581,8991,974
Other liabilities4862,854749   
Total noncurrent liabilities:53,62758,52057,86464,38314,41320,968
Total liabilities:78,94379,57383,17685,88928,45435,569
Stockholders' equity
Stockholders' equity attributable to parent, including:83,40176,68181,69482,72480,90072,196
Common stock452444438436419418
Additional paid in capital225,650232,357229,189226,377218,792215,134
Accumulated other comprehensive loss(10,027)(13,066)(12,689)(13,532)(10,676)(16,658)
Accumulated deficit(132,674)(132,386)(124,576)(119,889)(116,967)(116,030)
Other undisclosed stockholders' equity attributable to parent (10,668)(10,668)(10,668)(10,668)(10,668)
Total stockholders' equity:83,40176,68181,69482,72480,90072,196
TOTAL LIABILITIES AND EQUITY:162,344156,254164,870168,613109,354107,765

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues118,904102,100116,176120,774101,882104,521
Cost of revenue
(Cost of Goods and Services Sold)
(51,252)(44,059)(51,854)(57,593)(54,285)(56,106)
Gross profit:67,65258,04164,32263,18147,59748,415
Operating expenses(65,586)(57,820)(63,945)(62,197)(47,698)(51,412)
Operating income (loss):2,066221377984(101)(2,997)
Nonoperating expense(2,206)(7,513)(5,879)(8,959)(1,987)(81)
Foreign currency transaction gain (loss), before tax   148(534)737
Other nonoperating expense(666)(806)(469)(3,740)(740)(179)
Interest and debt expense (393)(385)(5,367)(713)(642)
Other undisclosed income from continuing operations before equity method investments, income taxes 3933855,367713642
Loss from continuing operations before income taxes:(140)(7,292)(5,502)(7,975)(2,088)(3,078)
Income tax expense (benefit)(148)(518)8153,6761,223(1,229)
Loss from continuing operations:(288)(7,810)(4,687)(4,299)(865)(4,307)
Income from discontinued operations   1,377  
Net loss available to common stockholders, diluted:(288)(7,810)(4,687)(2,922)(865)(4,307)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(288)(7,810)(4,687)(2,922)(865)(4,307)
Other comprehensive income (loss)3,039(377)843(2,856)5,982(4,774)
Comprehensive income (loss), net of tax, attributable to parent:2,751(8,187)(3,844)(5,778)5,117(9,081)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: